PI3Kδ/γ inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PI3Kδ/γ inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity
Authors
Keywords
-
Journal
BLOOD
Volume 139, Issue 4, Pages 523-537
Publisher
American Society of Hematology
Online
2022-01-28
DOI
10.1182/blood.2021011597
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Glycolysis fuels phosphoinositide 3-kinase signaling to bolster T cell immunity
- (2021) Ke Xu et al. SCIENCE
- First-in-human data of ALLO-501A, an allogeneic chimeric antigen receptor (CAR) T-cell therapy and ALLO-647 in relapsed/refractory large B-cell lymphoma (R/R LBCL): ALPHA2 study.
- (2021) Frederick Lundry Locke et al. JOURNAL OF CLINICAL ONCOLOGY
- Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial
- (2020) Carmen D. Herling et al. LEUKEMIA
- Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
- (2020) Enli Liu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fueling clonal dominance through TRAFficking of NF-κB signaling
- (2020) Koki Ueda et al. NATURE IMMUNOLOGY
- Ibrutinib for improved chimeric antigen receptor T‐cell production for chronic lymphocytic leukemia patients
- (2020) Fuli Fan et al. INTERNATIONAL JOURNAL OF CANCER
- NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019
- (2019) William G. Wierda et al. Journal of the National Comprehensive Cancer Network
- Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis
- (2019) Emma J.M. Grigor et al. TRANSFUSION MEDICINE REVIEWS
- Idelalisib for optimized CD19-specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients
- (2019) Sophia Stock et al. INTERNATIONAL JOURNAL OF CANCER
- Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T cell efficacy
- (2019) Jaco A. C. van Bruggen et al. BLOOD
- Chronic lymphocytic leukaemia: from genetics to treatment
- (2019) Francesc Bosch et al. Nature Reviews Clinical Oncology
- Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
- (2019) Tait D. Shanafelt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions
- (2019) Kirsten Fischer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Duvelisib for CLL/SLL and Follicular Non-Hodgkin Lymphoma
- (2019) Krish Patel et al. BLOOD
- Engaging Cytotoxic T and NK Cells for Immunotherapy in Chronic Lymphocytic Leukemia
- (2019) Tom Hofland et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T
- (2018) Dok Yoon et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
- (2018) Joseph A. Fraietta et al. NATURE MEDICINE
- Silencing stemness in T cell differentiation
- (2018) Amanda N. Henning et al. SCIENCE
- Diverse Roles of Mitochondria in Immune Responses: Novel Insights Into Immuno-Metabolism
- (2018) Anusha Angajala et al. Frontiers in Immunology
- High-Throughput Flow Cytometric Method for the Simultaneous Measurement of CAR-T Cell Characterization and Cytotoxicity against Solid Tumor Cell Lines
- (2018) Emily M. Martinez et al. SLAS Discovery
- Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group
- (2017) M A Hoechstetter et al. LEUKEMIA
- Autophagy maintains the metabolism and function of young and old stem cells
- (2017) Theodore T. Ho et al. NATURE
- T memory stem cells in health and disease
- (2017) Luca Gattinoni et al. NATURE MEDICINE
- FOXO1 opposition of CD8+T cell effector programming confers early memory properties and phenotypic diversity
- (2017) Arnaud Delpoux et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance
- (2017) Yinmeng Yang et al. Science Translational Medicine
- PI3Kδ Inhibition Enhances the Antitumor Fitness of Adoptively Transferred CD8+ T Cells
- (2017) Jacob S. Bowers et al. Frontiers in Immunology
- Development of chimeric antigen receptors targeting T-cell malignancies using two structurally different anti-CD5 antigen binding domains in NK and CRISPR-edited T cell lines
- (2017) Sunil S. Raikar et al. OncoImmunology
- Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity
- (2016) B. L. Lampson et al. BLOOD
- Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia
- (2016) Joseph A. Fraietta et al. BLOOD
- Mitochondrial Dynamics Controls T Cell Fate through Metabolic Programming
- (2016) Michael D. Buck et al. CELL
- CD4+T cell effector commitment coupled to self-renewal by asymmetric cell divisions
- (2016) Simone A. Nish et al. JOURNAL OF EXPERIMENTAL MEDICINE
- De novo DNA methylation by DNA methyltransferase 3a controls early effector CD8+T-cell fate decisions following activation
- (2016) Brian H. Ladle et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Genetic engineering of chimeric antigen receptors using lamprey derived variable lymphocyte receptors
- (2016) Robert Moot et al. Molecular Therapy-Oncolytics
- Idelalisib-associated Enterocolitis
- (2015) Christine Y. Louie et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Memory T cell–driven differentiation of naive cells impairs adoptive immunotherapy
- (2015) Christopher A. Klebanoff et al. JOURNAL OF CLINICAL INVESTIGATION
- Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
- (2015) David L. Porter et al. Science Translational Medicine
- Asymmetric PI3K Signaling Driving Developmental and Regenerative Cell Fate Bifurcation
- (2015) Wen-Hsuan W. Lin et al. Cell Reports
- Akt Inhibition Enhances Expansion of Potent Tumor-Specific Lymphocytes with Memory Cell Characteristics
- (2014) J. G. Crompton et al. CANCER RESEARCH
- Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
- (2014) M. L. Davila et al. Science Translational Medicine
- PI3K-δ and PI3K-γ Inhibition by IPI-145 Abrogates Immune Responses and Suppresses Activity in Autoimmune and Inflammatory Disease Models
- (2013) David G. Winkler et al. CHEMISTRY & BIOLOGY
- The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia
- (2013) D. Brusa et al. HAEMATOLOGICA
- T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production
- (2012) J. C. Riches et al. BLOOD
- Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer
- (2012) A. G. Ramsay et al. BLOOD
- Generation of Functional CLL-Specific Cord Blood CTL Using CD40-Ligated CLL APC
- (2012) William K. Decker et al. PLoS One
- B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
- (2011) J. N. Kochenderfer et al. BLOOD
- Definition and characterization of the systemic T-cell dysregulation in untreated indolent B-cell lymphoma and very early CLL
- (2011) P. Christopoulos et al. BLOOD
- Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias
- (2011) R. J. Brentjens et al. BLOOD
- Nurture versus Nature: The Microenvironment in Chronic Lymphocytic Leukemia
- (2011) J. A. Burger Hematology-American Society of Hematology Education Program
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started